Journal of the National Cancer Institute (JNCI)Endoxifen for Mammographic Density Reduction—Results from the KARISMA Endoxifen Trial

⚠️ Small Study / Early Comparative Evidence

KARISMA Endoxifen was a double-blind, randomized, placebo-controlled phase II trial evaluating whether direct endoxifen administration could reduce mammographic breast density in healthy premenopausal women. The strategy may bypass variability related to tamoxifen activation, but the trial evaluated a surrogate endpoint rather than cancer prevention.

Clinical Considerations

• Researchers randomized 240 women aged 40 to 55 years to placebo, 1 mg endoxifen, or 2 mg endoxifen daily for six months.
• Mammographic density declined 19.3% with 1 mg and 26.5% with 2 mg, compared with placebo after baseline-density adjustment.
• Density reduction appeared to plateau near endoxifen concentrations of 3 to 4 ng/mL, supporting further evaluation of the lower dose.
• Treatment-related adverse events affected 40% and 43% of the 1 mg and 2 mg groups, versus 20% with placebo.
• Treatment-related discontinuations occurred in 5 women receiving 1 mg and 11 receiving 2 mg, compared with 4 receiving placebo.
• The 2 mg dose increased hot flashes and night sweats, while 1 mg showed no significant worsening across assessed symptom categories.
• Low recruitment, short exposure, healthy volunteers, and reliance on density reduction limit generalizability and clinical interpretation.

Practice Applications

• Recognize that direct endoxifen administration avoids dependence on hepatic conversion of tamoxifen.
• Interpret mammographic density reduction as a response proxy, not proof of reduced breast cancer incidence.
• Consider the 1 mg dose the stronger tolerability signal for future prevention trials.
• Monitor future studies for cancer incidence, longer-term safety, adherence, and higher-risk population outcomes.
• Avoid extending these findings to routine breast cancer prevention or prescribing decisions.
• Discuss vasomotor and menstrual effects when contextualizing endocrine prevention research for premenopausal women.